m

FDA approves drug for hospital-acquired pneumonia

On May 23, the FDA approved a new drug intended to treat hospital-acquired pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus, a critical bacterial pathogen. 

The drug, Xacduro (sulbactam for injection; durlobactam for injection), works to simultaneously protect itself and kill A. baumannii. In a phase 3 trial, 19 percent of Xacduro patients died, compared to 32 percent of deaths among those who took colistin, a comparator antibiotic. 

A. baumannii tops the World Health Organization's list of critical pathogens that pose a high risk to human health, and the bacteria "can become highly resistant to multiple antibacterial drugs and current treatment options for drug-resistant A. baumannii are limited," the FDA said. 

Xacduro, made by Entasis Therapeutics, is approved for adults. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like